The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2 - PubMed (original) (raw)

The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2

T A Berkhout et al. Biochem J. 1990.

Abstract

(-)-Hydroxycitrate, a potent inhibitor of ATP citrate-lyase, was tested in Hep G2 cells for effects on cholesterol homoeostasis. After 2.5 h and 18 h incubations with (-)-hydroxycitrate at concentrations of 0.5 mM or higher, incorporation of [1,5-14C]citrate into fatty acids and cholesterol was strongly inhibited. This most likely reflects an effective inhibition of ATP citrate-lyase. Cholesterol biosynthesis was decreased to 27% of the control value as measured by incorporations from 3H2O, indicating a decreased flux of carbon units through the cholesterol-synthetic pathway. After 18 h preincubation with 2 mM-(-)-hydroxycitrate, the cellular low-density-lipoprotein (LDL) receptor activity was increased by 50%, as determined by the receptor-mediated association and degradation. Measurements of receptor-mediated binding versus LDL concentration suggests that this increase was due to an increase in the numbers of LDL receptors. Simultaneously, enzyme levels of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase as determined by activity measurements increased 30-fold. Our results suggest that the increases in HMG-CoA reductase and the LDL receptor are initiated by the decreased flux of carbon units in the cholesterol-synthetic pathway, owing to inhibition of ATP citratelyase. A similar induction of HMG-CoA reductase and LDL receptor was also found after preincubations of cells with 0.3 microM-mevinolin, suggesting that the underlying mechanism for this induction is identical for both drugs.

PubMed Disclaimer

Similar articles

• Enhancement of sterol synthesis by the monoterpene perillyl alcohol is unaffected by competitive 3-hydroxy-3-methylglutaryl-CoA reductase inhibition.
  Cerda SR, Wilkinson J 4th, Branch SK, Broitman SA. Cerda SR, et al. Lipids. 1999 Jun;34(6):605-15. doi: 10.1007/s11745-999-0405-5. Lipids. 1999. PMID: 10405975
• The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
  Berkhout TA, Simon HM, Patel DD, Bentzen C, Niesor E, Jackson B, Suckling KE. Berkhout TA, et al. J Biol Chem. 1996 Jun 14;271(24):14376-82. doi: 10.1074/jbc.271.24.14376. J Biol Chem. 1996. PMID: 8662919
• Evidence for sterol-independent regulation of low-density lipoprotein receptor activity in Hep-G2 cells.
  Ellsworth JL, Chandrasekaran C, Cooper AD. Ellsworth JL, et al. Biochem J. 1991 Oct 1;279 ( Pt 1)(Pt 1):175-87. doi: 10.1042/bj2790175. Biochem J. 1991. PMID: 1930137 Free PMC article.
• Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications.
  Nabi R, Alvi SS, Saeed M, Ahmad S, Khan MS. Nabi R, et al. Curr Diabetes Rev. 2019;15(3):213-223. doi: 10.2174/1573399814666180924113442. Curr Diabetes Rev. 2019. PMID: 30246643 Review.
• Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol.
  Goldstein JL, Brown MS. Goldstein JL, et al. J Lipid Res. 1984 Dec 15;25(13):1450-61. J Lipid Res. 1984. PMID: 6397553 Review. No abstract available.

Cited by

• Effects of garcinia cambogia (Hydroxycitric Acid) on visceral fat accumulation: a double-blind, randomized, placebo-controlled trial.
  Hayamizu K, Ishii Y, Kaneko I, Shen M, Okuhara Y, Shigematsu N, Tomi H, Furuse M, Yoshino G, Shimasaki H. Hayamizu K, et al. Curr Ther Res Clin Exp. 2003 Sep;64(8):551-67. doi: 10.1016/j.curtheres.2003.08.006. Curr Ther Res Clin Exp. 2003. PMID: 24944404 Free PMC article.
• Comparative de novo flower transcriptome analysis of polygamodioecious tree Garcinia indica.
  Patil RV, Pawar KD. Patil RV, et al. 3 Biotech. 2019 Mar;9(3):72. doi: 10.1007/s13205-019-1601-3. Epub 2019 Feb 9. 3 Biotech. 2019. PMID: 30800583 Free PMC article.
• Aberrant lipid metabolism as a therapeutic target in liver cancer.
  Pope ED 3rd, Kimbrough EO, Vemireddy LP, Surapaneni PK, Copland JA 3rd, Mody K. Pope ED 3rd, et al. Expert Opin Ther Targets. 2019 Jun;23(6):473-483. doi: 10.1080/14728222.2019.1615883. Epub 2019 May 10. Expert Opin Ther Targets. 2019. PMID: 31076001 Free PMC article. Review.
• Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
  Bilen O, Ballantyne CM. Bilen O, et al. Curr Atheroscler Rep. 2016 Oct;18(10):61. doi: 10.1007/s11883-016-0611-4. Curr Atheroscler Rep. 2016. PMID: 27663902 Free PMC article. Review.
• The vital role of ATP citrate lyase in chronic diseases.
  Khwairakpam AD, Banik K, Girisa S, Shabnam B, Shakibaei M, Fan L, Arfuso F, Monisha J, Wang H, Mao X, Sethi G, Kunnumakkara AB. Khwairakpam AD, et al. J Mol Med (Berl). 2020 Jan;98(1):71-95. doi: 10.1007/s00109-019-01863-0. Epub 2019 Dec 19. J Mol Med (Berl). 2020. PMID: 31858156 Review.

References

1. 1. Biochemistry. 1968 Oct;7(10):3708-17 - PubMed
2. 1. J Biol Chem. 1989 May 25;264(15):9046-52 - PubMed
3. 1. J Biol Chem. 1971 Feb 10;246(3):629-32 - PubMed
4. 1. Arch Biochem Biophys. 1972 May;150(1):183-90 - PubMed
5. 1. Eur J Biochem. 1973 Sep 21;38(1):98-102 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database